Epizyme (EPZM) Stock Forecast, Price & News

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Analyst Ratings Changes

A number of equities research analysts have commented on EPZM shares. Wedbush lowered Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. Cowen downgraded Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research note on Monday, June 27th. Cowen lowered Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price objective for the company. in a report on Monday, June 27th. StockNews.com raised Epizyme from a "sell" rating to a "hold" rating in a report on Monday, July 25th. Finally, HC Wainwright decreased their price objective on Epizyme from $8.00 to $6.00 and set a "buy" rating for the company in a report on Friday, June 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $3.50.

Epizyme Stock Up 2.7 %

EPZM Stock opened at $1.52 on Friday. The business has a 50 day moving average of $1.15 and a 200-day moving average of $1.14. Epizyme has a 12-month low of $0.41 and a 12-month high of $6.67.

Epizyme (NASDAQ:EPZM - Get Rating) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). Epizyme had a negative return on equity of 2,459.33% and a negative net margin of 614.08%. The business had revenue of $8.70 million during the quarter, compared to analysts' expectations of $10.86 million. During the same quarter last year, the business posted ($0.69) EPS. As a group, analysts expect that Epizyme will post -1.38 EPS for the current year.